S. Hegewisch-Becker

1.8k total citations
40 papers, 1.1k citations indexed

About

S. Hegewisch-Becker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, S. Hegewisch-Becker has authored 40 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in S. Hegewisch-Becker's work include Colorectal Cancer Treatments and Studies (12 papers), Gastric Cancer Management and Outcomes (9 papers) and Cancer Treatment and Pharmacology (6 papers). S. Hegewisch-Becker is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Gastric Cancer Management and Outcomes (9 papers) and Cancer Treatment and Pharmacology (6 papers). S. Hegewisch-Becker collaborates with scholars based in Germany, United States and Austria. S. Hegewisch-Becker's co-authors include Ullrich Graeven, Wolff Schmiegel, Dirk Arnold, Dieter K. Hossfeld, Hans‐Joachim Schmoll, Andrea Tannapfel, Nicolaus Kröger, Ewald Wöll, Falko Fend and Gunnar Folprecht and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

S. Hegewisch-Becker

37 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Hegewisch-Becker Germany	20	665	395	215	170	167	40	1.1k
Myung Soo Hyun South Korea	18	377 0.6×	179 0.5×	302 1.4×	122 0.7×	195 1.2×	77	1.1k
B. Mirtsching United States	12	1.1k 1.7×	459 1.2×	182 0.8×	131 0.8×	126 0.8×	27	1.3k
H.‐G. Mergenthaler Germany	12	543 0.8×	212 0.5×	111 0.5×	105 0.6×	206 1.2×	33	903
Jacob R. Izbicki Germany	18	576 0.9×	357 0.9×	284 1.3×	394 2.3×	66 0.4×	47	1.3k
Roopinder Gillmore United Kingdom	15	684 1.0×	233 0.6×	176 0.8×	322 1.9×	131 0.8×	49	1.3k
Myung Hee Chang South Korea	17	385 0.6×	246 0.6×	118 0.5×	131 0.8×	205 1.2×	50	718
Keon Woo Park South Korea	14	707 1.1×	598 1.5×	161 0.7×	387 2.3×	333 2.0×	44	1.3k
Keisuke Aiba Japan	15	500 0.8×	284 0.7×	194 0.9×	333 2.0×	149 0.9×	71	992
Anna Russo Italy	18	550 0.8×	269 0.7×	107 0.5×	247 1.5×	477 2.9×	74	1.1k
Carlyn Tan United States	15	533 0.8×	424 1.1×	289 1.3×	209 1.2×	258 1.5×	60	1.3k

Countries citing papers authored by S. Hegewisch-Becker

Since Specialization

Citations

This map shows the geographic impact of S. Hegewisch-Becker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Hegewisch-Becker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Hegewisch-Becker more than expected).

Fields of papers citing papers by S. Hegewisch-Becker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Hegewisch-Becker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Hegewisch-Becker. The network helps show where S. Hegewisch-Becker may publish in the future.

Co-authorship network of co-authors of S. Hegewisch-Becker

This figure shows the co-authorship network connecting the top 25 collaborators of S. Hegewisch-Becker. A scholar is included among the top collaborators of S. Hegewisch-Becker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Hegewisch-Becker. S. Hegewisch-Becker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stintzing, Sebastian, Richard Greil, Jens Kisro, et al.. (2025). 40P Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma - Effectiveness and treatment reality of the European multi-centric, multi-national, non-interventional study: BERING CRC. Annals of Oncology. 36. S25–S25.

Hofheinz, Ralf‐Dieter, S. Hegewisch-Becker, Volker Kunzmann, et al.. (2021). Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. International Journal of Cancer. 149(6). 1322–1331. 59 indexed citations

Modest, Dominik Paul, Ingrid Ricard, Volker Heinemann, et al.. (2016). Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Annals of Oncology. 27(9). 1746–1753. 213 indexed citations

Jordan, Karin, Tim Luetkens, C. Gog, et al.. (2016). Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study – AIO SUP-0108. European Journal of Cancer. 63. 127–134. 20 indexed citations

Gießen, Clemens, Ullrich Graeven, Rüdiger P. Laubender, et al.. (2013). Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group. Annals of Oncology. 24(12). 3051–3055. 8 indexed citations

Lordick, Florian, Birgit Luber, Sylvie Lorenzen, et al.. (2010). Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). British Journal of Cancer. 102(3). 500–505. 141 indexed citations

Trarbach, Tanja, Anke Reinacher‐Schick, S. Hegewisch-Becker, et al.. (2010). Gefitinib in Combination with Capecitabine as Second-Line Therapy in Patients with Advanced Colorectal Cancer (aCRC): A Phase I/II Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Onkologie. 33(3). 89–93. 9 indexed citations

Panse, Jens, Kay Friedrichs, Alexander Marx, et al.. (2008). Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. British Journal of Cancer. 99(6). 930–938. 100 indexed citations

Reinacher-Schick, A., Stefan Kubicka, Werner Freier, et al.. (2008). Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). Journal of Clinical Oncology. 26(15_suppl). 4030–4030. 36 indexed citations

10.

Hildebrandt, Bert, S. Hegewisch-Becker, Thoralf Kerner, et al.. (2004). Current status of radiant whole-body hyperthermia at temperatures >41.5°C and practical guidelines for the treatment of adults. The German ‘Interdisciplinary Working Group on Hyperthermia’. International Journal of Hyperthermia. 21(2). 169–183. 43 indexed citations

11.

Bruns, Ingmar, Anne M. Traynor, H. Ian Robins, et al.. (2003). Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma. Lung Cancer. 39(3). 339–345. 23 indexed citations

12.

Länger, Florian, Barbara Eifrig, Gerald R. Marx, et al.. (2002). Exacerbation of antiphospholipid antibody syndrome after treatment of localized cancer: a report of two cases. Annals of Hematology. 81(12). 727–731. 19 indexed citations

13.

Hegewisch-Becker, S., et al.. (2001). Neue Indikationen für Thalidomid?. DMW - Deutsche Medizinische Wochenschrift. 126(42). 1178–1182. 2 indexed citations

14.

Kehrl, W., S. Hegewisch-Becker, S. Wenzel, et al.. (2000). Tumoroxygenierung unter kombinierter Ganzkörperhyperthermie und Polychemotherapie. HNO. 48(12). 949–954. 1 indexed citations

15.

Kröger, Nicolaus, W. Achterrath, S. Hegewisch-Becker, K. Mross, & A R Zander. (1999). Current options in treatment of anthracycline-resistant breast cancer. Cancer Treatment Reviews. 25(5). 279–291. 62 indexed citations

16.

Kröger, Nicolaus, William Krüger, S. Hegewisch-Becker, et al.. (1998). Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplantation. 22(11). 1029–1033. 21 indexed citations

17.

Hegewisch-Becker, S. & Dieter K. Hossfeld. (1996). The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. Annals of Hematology. 72(3). 105–117. 22 indexed citations

18.

Andreeff, Michael, Saili Zhao, Doris Drach, et al.. (1993). Expression of multidrug resistance (mdr-1) and p53 genes in hematologic cell systems: Implications for biology and gene therapy. 45(2). 131–138. 4 indexed citations

19.

Hegewisch-Becker, S., et al.. (1993). Multidrug Resistance (mdr1) in Adult Acute Leukemia at Diagnosis: Correlation with Response to Induction Chemotherapy. Oncology Research and Treatment. 16(4). 264–269. 4 indexed citations

20.

Andreeff, Michael, Agostino Tafuri, & S. Hegewisch-Becker. (1990). Colony-Stimulating Factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCFG) Recruit Myeloblastic and Lymphoblastic Leukemic Cells and Enhance the Cytotoxic Effects of Cytosine-Arabinoside. Hämatologie und Bluttransfusion. 33. 747–762. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact